Ilaris (canakinumab)
An approved treatment for Systemic Juvenile Idiopathic Arthritis.
The same compound appears under different names depending on the context. Here is how to identify Canakinumab wherever you encounter it, plus the key facts at a glance.
- Generic name
- Canakinumab
- Brand name
- Ilaris
- Development code
- ACZ885
- Drug class
- Anti-IL-1β monoclonal antibody
- Manufacturer
- Novartis
- How it's taken
- Given as a subcutaneous injection (under the skin), 4 mg/kg every 4 weeks.
A monthly injection that blocks IL-1β, the key inflammatory protein driving systemic JIA. In pivotal trials, 84% of children achieved rapid symptom improvement within 15 days, and a third were able to discontinue corticosteroids entirely.
Where Canakinumab fits
First-line biologic option for systemic JIA alongside tocilizumab. The IL-1 pathway is central to sJIA pathogenesis, making IL-1 inhibitors particularly effective. Monthly dosing offers convenience over daily anakinra injections. Choice between canakinumab and tocilizumab often depends on whether systemic features (favoring IL-1 blockade) or arthritis (potentially favoring IL-6 blockade) predominate.
How Canakinumab works
In systemic JIA, the immune system overproduces a protein called IL-1β that triggers intense, body-wide inflammation causing spiking fevers, salmon-pink rash, and joint destruction. Canakinumab is a laboratory-made antibody that circulates through the bloodstream and intercepts IL-1β molecules before they can activate immune cells.
When canakinumab binds to IL-1β, it neutralizes the protein and prevents it from reaching its receptors on cells. Without this signal, the inflammatory cascade that causes fevers, rash, and joint damage is interrupted. The effect is often dramatic, with many children experiencing resolution of systemic symptoms within days of the first dose.
Because canakinumab has a long half-life, it only needs to be injected once every 4 weeks. This makes it more convenient than anakinra (which requires daily injections) and allows for sustained IL-1β suppression throughout the dosing interval.
Mechanism: Fully human monoclonal antibody that selectively binds and neutralizes interleukin-1 beta (IL-1β), blocking the inflammatory cascade that drives systemic JIA symptoms
Side effects and safety
The most common side effects include injection site reactions (redness, pain, itching at the injection site), upper respiratory infections, nasopharyngitis, abdominal pain, headache, and nausea. Because canakinumab suppresses part of the immune system, there is an increased risk of infections. Neutropenia (low white blood cell counts) can occur and requires monitoring. Patients should not receive live vaccines while on treatment. Your doctor will test for tuberculosis (TB) before starting. Get medical help right away for signs of a serious allergic reaction, including a rare but severe reaction called DRESS that causes a serious skin rash. Macrophage activation syndrome (MAS), a life-threatening complication of systemic JIA, can still happen during treatment, and infections or disease flares can trigger it, so report fever or new symptoms to your child's doctor right away. The label also notes that medicines that weaken the immune system may raise the risk of cancer.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Canakinumab
Given as a subcutaneous injection (under the skin), 4 mg/kg every 4 weeks. The maximum single dose is 300 mg. It comes in single-dose vials and is given by a healthcare provider. The ILARIS Companion support program can arrange for a nurse to give the injection at home.
Availability and cost
Only available as the brand-name product.
Help paying for Ilaris
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
Eligible commercially insured patients pay no more than $30 per month, subject to an annual cap. Federal or state program patients not eligible.
For: private insurance · source - Insurance and case manager help
Benefits checks, prior authorization and appeals help, identifying support for uninsured and underinsured patients, delivery coordination, and home nurse injections.
The official page does not say who qualifies. Ask the program. · source - Other support
Free Trial Offer: one starter dose of Ilaris at no cost for new patients with urgent medical need, regardless of insurance. One-time use.
The official page does not say who qualifies. Ask the program. · source - Free medicine program
Novartis Patient Assistance Foundation provides Ilaris free to eligible patients who are uninsured or have government insurance and meet income limits.
For: no insurance, Medicare, Medicaid · source
Good to know: Free drug is through the separate Novartis Patient Assistance Foundation (1-800-277-2254); income limits apply. Program hours Mon-Fri 9 AM-6 PM ET.
- From a charity · The Assistance FundJuvenile Arthritis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Clinical trial results
2 pivotal Phase 3 randomized controlled trials enrolled children with active systemic JIA. In the first trial, 84% of canakinumab-treated patients achieved JIA ACR30 response by day 15, compared to just 10% on placebo. Among responders, 74% remained flare-free versus 25% on placebo. Across both trials, 73% achieved JIA ACR50 and 31% reached inactive disease status. Corticosteroid doses dropped from 0.34 to 0.05 mg/kg/day, with 33% of patients discontinuing steroids entirely.
Development history
Novartis developed canakinumab (ACZ885) as a highly specific IL-1β inhibitor. It was first approved in 2009 for cryopyrin-associated periodic syndromes (CAPS). Following successful trials demonstrating rapid resolution of systemic JIA symptoms, FDA approved canakinumab for sJIA in May 2013 in patients aged 2 and older. It remains one of the cornerstone biologic therapies for this condition.
Explore Systemic Juvenile Idiopathic Arthritis trials
Other Systemic Juvenile Idiopathic Arthritis treatments
Common questions about Canakinumab
▸What is Canakinumab (Ilaris)?
A monthly injection that blocks IL-1β, the key inflammatory protein driving systemic JIA. In pivotal trials, 84% of children achieved rapid symptom improvement within 15 days, and a third were able to discontinue corticosteroids entirely.
▸How does Canakinumab work?
In systemic JIA, the immune system overproduces a protein called IL-1β that triggers intense, body-wide inflammation causing spiking fevers, salmon-pink rash, and joint destruction. Canakinumab is a laboratory-made antibody that circulates through the bloodstream and intercepts IL-1β molecules before they can activate immune cells.
When canakinumab binds to IL-1β, it neutralizes the protein and prevents it from reaching its receptors on cells. Without this signal, the inflammatory cascade that causes fevers, rash, and joint damage is interrupted. The effect is often dramatic, with many children experiencing resolution of systemic symptoms within days of the first dose.
Because canakinumab has a long half-life, it only needs to be injected once every 4 weeks. This makes it more convenient than anakinra (which requires daily injections) and allows for sustained IL-1β suppression throughout the dosing interval.
▸What are the side effects of Canakinumab?
The most common side effects include injection site reactions (redness, pain, itching at the injection site), upper respiratory infections, nasopharyngitis, abdominal pain, headache, and nausea. Because canakinumab suppresses part of the immune system, there is an increased risk of infections. Neutropenia (low white blood cell counts) can occur and requires monitoring. Patients should not receive live vaccines while on treatment. Your doctor will test for tuberculosis (TB) before starting. Get medical help right away for signs of a serious allergic reaction, including a rare but severe reaction called DRESS that causes a serious skin rash. Macrophage activation syndrome (MAS), a life-threatening complication of systemic JIA, can still happen during treatment, and infections or disease flares can trigger it, so report fever or new symptoms to your child's doctor right away. The label also notes that medicines that weaken the immune system may raise the risk of cancer.
▸How is Canakinumab taken?
Given as a subcutaneous injection (under the skin), 4 mg/kg every 4 weeks. The maximum single dose is 300 mg. It comes in single-dose vials and is given by a healthcare provider. The ILARIS Companion support program can arrange for a nurse to give the injection at home.
▸Is Canakinumab FDA approved?
Yes, Canakinumab (Ilaris) is FDA approved (2013) for the treatment of Systemic Juvenile Idiopathic Arthritis.
▸What is Ilaris used for in systemic JIA?
Ilaris (canakinumab) is an FDA-approved IL-1 beta blocker for systemic juvenile idiopathic arthritis in children aged 2 and older. It targets the key inflammatory protein that causes fevers, rash, and joint destruction in sJIA.
▸How quickly does canakinumab work for sJIA?
Canakinumab works rapidly. In clinical trials, 84% of children achieved significant symptom improvement within just 15 days of the first dose, and a third were able to stop corticosteroids entirely.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- New England Journal of Medicine · 2012. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. https://www.nejm.org/doi/full/10.1056/NEJMoa1205099
- U.S. Food and Drug Administration. ILARIS (canakinumab) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s107lbl.pdf
- Novartis Pharmaceuticals. Ilaris (canakinumab) for Systemic JIA. https://www.ilaris.com